- Home
- EYPT vs COLL Comparison
EYPT vs COLL Comparison
Compare EYPT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- COLL
- Stock Information
- Founded
- EYPT 1987
- COLL 2002
- Country
- EYPT United States
- COLL United States
- Employees
- EYPT N/A
- COLL N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- COLL Health Care
- Exchange
- EYPT Nasdaq
- COLL Nasdaq
- Market Cap
- EYPT 967.4M
- COLL 1.1B
- IPO Year
- EYPT 2005
- COLL 2015
- Fundamental
- Price
- EYPT $14.50
- COLL $45.71
- Analyst Decision
- EYPT Strong Buy
- COLL Strong Buy
- Analyst Count
- EYPT 5
- COLL 5
- Target Price
- EYPT $29.60
- COLL $45.40
- AVG Volume (30 Days)
- EYPT 1.4M
- COLL 549.9K
- Earning Date
- EYPT 11-05-2025
- COLL 11-06-2025
- Dividend Yield
- EYPT N/A
- COLL N/A
- EPS Growth
- EYPT N/A
- COLL N/A
- EPS
- EYPT N/A
- COLL 1.63
- Revenue
- EYPT $42,339,000.00
- COLL $757,067,000.00
- Revenue This Year
- EYPT N/A
- COLL $21.41
- Revenue Next Year
- EYPT N/A
- COLL $3.28
- P/E Ratio
- EYPT N/A
- COLL $28.10
- Revenue Growth
- EYPT N/A
- COLL 26.34
- 52 Week Low
- EYPT $3.91
- COLL $23.23
- 52 Week High
- EYPT $14.91
- COLL $48.18
- Technical
- Relative Strength Index (RSI)
- EYPT 65.45
- COLL 70.64
- Support Level
- EYPT $13.43
- COLL $43.12
- Resistance Level
- EYPT $14.67
- COLL $46.48
- Average True Range (ATR)
- EYPT 0.91
- COLL 1.83
- MACD
- EYPT 0.32
- COLL 0.04
- Stochastic Oscillator
- EYPT 99.54
- COLL 71.98
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.